Pediatric Drugs
Leading citation impact metric from Clarivate Journal Citation Reports
55 papers with at least that number of citations each
State Council for Professorship (HĐGSNN) Scoring
Quyết định số 26/QĐ-HĐGSNN ngày 11/7/2025 (Mục quốc tế)
HĐGSNN Score History
By article publication year| Year | Max Score | Evaluation Details | Source |
|---|---|---|---|
| 2026 | 2.50đ | WoS Q1 có IF ≥ 3.0(IF: 3.7) | 🔵 Computed |
| 2025 | 2.50đ | WoS Q1 có IF ≥ 3.0(IF: 3.3) | 🔵 Computed |
| 2024 | 2.50đ | WoS Q1 có IF ≥ 3.0(IF: 3.4) | 🔵 Computed |
| 2023 | 2.50đ | WoS Q1 có IF ≥ 3.0(IF: 3.7) | 🔵 Computed |
| 2022 | 2.50đ | WoS Q1 có IF ≥ 3.0(IF: 3.93) | 🔵 Computed |
| 2021 | 2.50đ | WoS Q1 có IF ≥ 3.0(IF: 3.022) | 🔵 Computed |
| 2020 | 2.00đ | WoS Q1(IF: 2.519) | 🔵 Computed |
| 2019 | 2.00đ | WoS Q1(IF: 1.76) | 🔵 Computed |
| 2018 | 2.00đ | WoS Q1(IF: 2) | 🔵 Computed |
Note: Domestic journal scores are officially collected from annual HĐGSNN decisions across councils. International journal scores are dynamically computed according to Decision 26/QĐ-HĐGSNN based on quartile and citation metrics in the publication year.
Aims & Scope
Pediatric Drugs promotes the optimization and advancement of all aspects of pharmacotherapy for healthcare professionals interested in pediatric drug therapy (including vaccines). The program of review and original research articles provides healthcare decision makers with clinically applicable knowledge on issues relevant to drug therapy in all areas of neonatology and the care of children and adolescents. The Journal includes: -overviews of contentious or emerging issues. -comprehensive narrative reviews of topics relating to the effective and safe management of drug therapy through all stages of pediatric development. -practical reviews covering optimum drug management of specific clinical situations. -systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement. -Adis Drug Reviews of the properties and place in therapy of both newer and established drugs in the pediatric population. -original research articles reporting the results of well-designed studies with a strong link to clinical practice, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research, and pharmacoeconomic and pharmacoepidemiological studies. Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Pediatric Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.
SCImago & Scopus Journal Intelligence
Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact
Weighted prestige citation metric per document indexed in the Scopus database.
Measures cumulative publication volume and citation impact.
Average citations received per document published in the 2-year window.
Estimated Article Processing Charge for Open Access publication.
Scopus 3-Year Publication & Citation Window
Aggregated from Scopus database across the 3-year SJR evaluation window.
Societal Impact & Inclusivity (SCImago)
Citations in government and international policy documents
Percentage of female authors published in the journal
Real-world societal policy reach and author gender diversity tracked by SCImago.
Scopus Subject Categories
Chinese Academy of Sciences (CAS) Classification
Major / minor zone classification and CAS Early Warning List history
Publishing & Editorial Information
Detailed publisher, peer-review turnaround, and publication cycle specifications
WoS Categories & Quartiles
Detailed JCR / JCI category rankings and quartile breakdown from Clarivate
| Category | Index | Rank | Quartile |
|---|---|---|---|
PEDIATRICS | JCRSCIE | 16/190 | Q1 |
PHARMACOLOGY & PHARMACY | JCRSCIE | 120/356 | Q2 |
PEDIATRICS | JCISCIE | 44/190 | Q1 |
PHARMACOLOGY & PHARMACY | JCISCIE | 76/356 | Q1 |
Annual Historical Statistics & Publications
Track annual publication volume, total citations, and Impact Factor evolution
| Year | Impact Factor | Articles / Year | Total Citations |
|---|---|---|---|
| 2026 | — | 36 | 12 |
| 2025 | 3.3 | 59 | 161 |
| 2024 | 3.4 | 62 | 496 |
| 2023 | 3.7 | 57 | 694 |
| 2022 | 3.93 | 65 | 1,027 |
| 2021 | 3.022 | 55 | 1,255 |
| 2020 | 2.519 | 61 | 1,790 |
| 2019 | 1.76 | 47 | 1,517 |
| 2018 | 2 | 42 | 1,047 |
| 2017 | — | 70 | 1,754 |
| 2016 | — | 49 | 1,300 |
| 2015 | — | 45 | 1,578 |
Journal Metrics & Citation Visualizations
Impact Factor Trend (2018–2024)
Clarivate IF trend for Pediatric Drugs
Total Cites vs Self-Cites
Evaluation of scholarly independence and citation reach
Citations per Document
Citation metric windows across 2, 3, and 4 years
Similar Journals in Discipline
Journals in the same research field with comparable impact metrics